Announcements
- Addex’s Partner Discontinues ADX71149 development in Epilepsy
- Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
- Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
- Addex Shareholders Approve All Resolutions at Annual General Meeting
- Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
- Addex Convenes Annual General Meeting 2024
- Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
- Addex to Present at Bio€quity Europe 2024
- Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
- Addex to Present at the Swiss Biotech Day 2024
More ▼
Key statistics
On Friday, Addex Therapeutics Ltd (APE1:FRA) closed at 6.65, 47.78% above the 52 week low of 4.50 set on Feb 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.65 |
---|---|
High | 6.65 |
Low | 6.65 |
Bid | 6.65 |
Offer | 8.10 |
Previous close | 6.65 |
Average volume | 0.00 |
---|---|
Shares outstanding | 1.54m |
Free float | 1.48m |
P/E (TTM) | -- |
Market cap | 13.13m USD |
EPS (TTM) | -15.15 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 14:29 BST.
More ▼